Idera Pharmaceuticals, Inc is a biotechnology business based in the US. Idera Pharmaceuticals shares (IDRA) are listed on the NASDAQ and all prices are listed in US Dollars. Idera Pharmaceuticals employs 32 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Idera Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IDRA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Idera Pharmaceuticals stock price (NASDAQ: IDRA)Use our graph to track the performance of IDRA stocks over time.
Idera Pharmaceuticals shares at a glance
|Latest market close||$1.17|
|52-week range||$0.97 - $6.14|
|50-day moving average||$1.16|
|200-day moving average||$2.49|
|Wall St. target price||$1.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.66|
Buy Idera Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Idera Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Idera Pharmaceuticals price performance over time
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||1.17|
|3 months (2021-05-04)||2.63%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
Idera Pharmaceuticals financials
|Gross profit TTM||$-16,707,000|
|Return on assets TTM||-49.31%|
|Return on equity TTM||-27.23%|
|Market capitalisation||$52.5 million|
TTM: trailing 12 months
Shorting Idera Pharmaceuticals shares
There are currently 2.5 million Idera Pharmaceuticals shares held short by investors – that's known as Idera Pharmaceuticals's "short interest". This figure is 24.9% down from 3.3 million last month.
There are a few different ways that this level of interest in shorting Idera Pharmaceuticals shares can be evaluated.
Idera Pharmaceuticals's "short interest ratio" (SIR)
Idera Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Idera Pharmaceuticals shares currently shorted divided by the average quantity of Idera Pharmaceuticals shares traded daily (recently around 5.2 million). Idera Pharmaceuticals's SIR currently stands at 0.48. In other words for every 100,000 Idera Pharmaceuticals shares traded daily on the market, roughly 480 shares are currently held short.
However Idera Pharmaceuticals's short interest can also be evaluated against the total number of Idera Pharmaceuticals shares, or, against the total number of tradable Idera Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Idera Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Idera Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0649% of the tradable shares (for every 100,000 tradable Idera Pharmaceuticals shares, roughly 65 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Idera Pharmaceuticals.
Find out more about how you can short Idera Pharmaceuticals stock.
Idera Pharmaceuticals share dividends
We're not expecting Idera Pharmaceuticals to pay a dividend over the next 12 months.
Have Idera Pharmaceuticals's shares ever split?
Idera Pharmaceuticals's shares were split on a 1:8 basis on 29 July 2018. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Idera Pharmaceuticals shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Idera Pharmaceuticals shares which in turn could have impacted Idera Pharmaceuticals's share price.
Idera Pharmaceuticals share price volatility
Over the last 12 months, Idera Pharmaceuticals's shares have ranged in value from as little as $0.97 up to $6.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Idera Pharmaceuticals's is 1.8172. This would suggest that Idera Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Idera Pharmaceuticals overview
Idera Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Stocks similar to Idera Pharmaceuticals
Idera Pharmaceuticals in the news
BioCryst appoints Vincent Milano to board of directors
Tracking Baker Brothers Portfolio - Q1 2021 Update
Frequently asked questionsWhat percentage of Idera Pharmaceuticals is owned by insiders or institutions?
Currently 22.619% of Idera Pharmaceuticals shares are held by insiders and 19.736% by institutions. How many people work for Idera Pharmaceuticals?
Latest data suggests 32 work at Idera Pharmaceuticals. When does the fiscal year end for Idera Pharmaceuticals?
Idera Pharmaceuticals's fiscal year ends in December. Where is Idera Pharmaceuticals based?
Idera Pharmaceuticals's address is: 505 Eagleview Boulevard, Exton, PA, United States, 19341 What is Idera Pharmaceuticals's ISIN number?
Idera Pharmaceuticals's international securities identification number is: US45168K4058 What is Idera Pharmaceuticals's CUSIP number?
Idera Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 44860M108
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert